Agent delays bone metastases in men with castration-resistant prostate cancer

The RANK ligand inhibitor denosumab (XGEVA) may be able to prevent or at least delay multiple and/or symptomatic bone metastases in men with castration-resistant prostate cancer (CRPC) at high risk of bone metastases.

Related Videos

Related Content

Advertisement

January 24th 2025

Desai Sethi Urology Institute shares inaugural Annual Report

University of Miami Health System Desai Sethi Urology Institute

The report, titled "TRANSFORMATION: From an academic department to a leading Institute," highlights DSUI's transformation from a department into a multidisciplinary institute.

January 14th 2025

Episode 2 Podcast: Managing Overactive Bladder: From Dual Diagnoses to Geriatric Challenges

Wayne Kuang, MD Steven Maislos, MD

Panelists discuss how managing overactive bladder in older adults requires a holistic approach that integrates treatment of comorbidities, emerging therapeutic options, and quality-of-life considerations to optimize patient outcomes.

January 24th 2025

Call for Abstract, Workshop, and Roundtable Submissions for PFD Week 2025

American Urogynecologic Society

Submit your abstract and/or roundtable and workshop proposal for PFD Week 2025, to be held October 14-17 in Vancouver, Canada!

November 27th 2024

Episode 1 Podcast: Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults

Wayne Kuang, MD Bilal Chughtai, MD

Experts discuss overactive bladder and the impacts on quality of life, distinguishing OAB from BPH, and how a delayed diagnosis can worsen symptoms.

January 24th 2025

Take Charge of 2025: A Financial Webinar Series for Physicians

American Urogynecologic Society

We're excited to announce a new four-part webinar series designed to educate and empower physicians with financial tools and insights needed to prosper in 2025 and beyond.

January 24th 2025

FDA fast tracks 64Cu-SAR-bisPSMA for biochemically recurrent prostate cancer

Hannah Clarke

64Cu-SAR-bisPSMA was previously granted a fast track designation in August 2024 for PET imaging of PSMA-positive prostate cancer lesions in patients with suspected metastasis who are candidates for initial definitive therapy.

Related Content

Advertisement

January 24th 2025

Desai Sethi Urology Institute shares inaugural Annual Report

University of Miami Health System Desai Sethi Urology Institute

The report, titled "TRANSFORMATION: From an academic department to a leading Institute," highlights DSUI's transformation from a department into a multidisciplinary institute.

January 14th 2025

Episode 2 Podcast: Managing Overactive Bladder: From Dual Diagnoses to Geriatric Challenges

Wayne Kuang, MD Steven Maislos, MD

Panelists discuss how managing overactive bladder in older adults requires a holistic approach that integrates treatment of comorbidities, emerging therapeutic options, and quality-of-life considerations to optimize patient outcomes.

January 24th 2025

Call for Abstract, Workshop, and Roundtable Submissions for PFD Week 2025

American Urogynecologic Society

Submit your abstract and/or roundtable and workshop proposal for PFD Week 2025, to be held October 14-17 in Vancouver, Canada!

November 27th 2024

Episode 1 Podcast: Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults

Wayne Kuang, MD Bilal Chughtai, MD

Experts discuss overactive bladder and the impacts on quality of life, distinguishing OAB from BPH, and how a delayed diagnosis can worsen symptoms.

January 24th 2025

Take Charge of 2025: A Financial Webinar Series for Physicians

American Urogynecologic Society

We're excited to announce a new four-part webinar series designed to educate and empower physicians with financial tools and insights needed to prosper in 2025 and beyond.

January 24th 2025

FDA fast tracks 64Cu-SAR-bisPSMA for biochemically recurrent prostate cancer

Hannah Clarke

64Cu-SAR-bisPSMA was previously granted a fast track designation in August 2024 for PET imaging of PSMA-positive prostate cancer lesions in patients with suspected metastasis who are candidates for initial definitive therapy.